Opiate Receptors and Antagonists: From Bench to Clinic (Contemporary Neuroscience)

The evolution in our understanding of Opioid receptors and their subtypes is intimately linked to the development of new pharmacological treatments for diseases and disorders as diverse as addiction, self-injurious behavior, pain, cancer, inflammation, eating disorders, traumatic injury, pruritis and movement disorders. The contributions contained in Opioid Receptors and Antagonists: From Bench to Clinic represent efforts from leading international scientists and clinicians making use of the latest information emerging from the study of the opioid-receptor system. The authors use a variety of experimental and clinical approaches involving the fields of molecular biology, biochemistry, anatomy, pharmacology, behavioral neuroscience and psychiatry to illustrate rapidly developing experimental and therapeutic areas. Highlights include characterization of opioid receptors, chemistry and pharmacology of opiod antagonists for various receptor subtypes (Mu, Kappa, and Delta), discussion of therapeutic uses of opiod antagonists and exploration of innovative approaches to therapeutic drug delivery. Opioid Receptors and Antagonists: From Bench to Clinic offers a comprehensive view of recent work on opiod antagonist applications and uses in various clinical treatments. Emphasis is placed on disorders of the reward system. This volume serves as reference while also illuminating prospects for future research. Front Matter....Pages i-xxiii Ultra-Low-Dose Opioid Antagonists Enhance Opioid Analgesia and Reduce Tolerance....Pages 3-17 Upregulation of Opioid Receptors....Pages 19-44 Imaging Human Brain Opioid Receptors: Applications to Substance Use Disorders....Pages 45-65 Opioid Receptor Antagonist-Mediated Signaling in the Immune System....Pages 67-80 The Chemistry and Pharmacology of μ-Opioid Antagonists....Pages 83-97 Medicinal Chemistry of Kappa Opioid Receptor Antagonists....Pages 99-118 The Chemistry and Pharmacology of Delta Opioid Antagonists....Pages 119-136 Novel Opioid Antagonists with Mixed/Dual Selectivity....Pages 137-151 Experimental Utility and Clinical Potential of Irreversible Opioid Antagonists....Pages 153-174 Methylnaltrexone: A Peripherally Acting Opioid Antagonist....Pages 175-198 Opioid Antagonist Effects in Animal Models Related to Opioid Abuse: Drug Discrimination and Drug Self-Administration....Pages 201-226 Naltrexone for Initiation and Maintenance of Opiate Abstinence....Pages 227-245 Ultra-Low-Dose Naltrexone Decreases Dependence and Addictive Properties of Opioids....Pages 247-261 Can a Combination Formulation Containing a Neutral Opiate Antagonist Decrease the Abuse of μ-Agonist Opiates....Pages 263-272 Effects of Opioid Antagonists on the Abuse-Related Effects of Psychomotor Stimulants and Nicotine....Pages 273-298 Potential Use of Opioid Antagonists in the Treatment of Marijuana Abuse and Dependence....Pages 299-314 Naltrexone in Smoking Cessation: A Review of the Literature and Future Directions....Pages 315-332 Opioid Antagonists and Ethanol's Ability to Reinforce Intake of Alcoholic Beverages: Preclinical Studies....Pages 335-369 Clinical Use of Opioid Antagonists in the Treatment of Alcohol Dependence....Pages 371-386 Preclinical Effects of Opioid Antagonists on Feeding and Appetite....Pages 387-406 CNS Opiate Systems and Eating Disorders....Pages 407-421 Potential Utility of Kappa Ligands in the Treatment of Mood Disorders....Pages 425-444 Opioid Antagonists in the Treatment of Pathological Gambling and Kleptomania....Pages 445-456 Efficacy of Opioid Antagonists in Attentuating Self-Injurious Behavior....Pages 457-472 Pharmacotherapeutic Effects of Opioid Antagonists in Alcohol-Abusing Patients with Schizophrenia....Pages 473-483 Current Issues in the Use of Opioid Antagonists (Naltrexone for Opiate Abuse: A Re-Educational Tool as Well as an Effective Drug)....Pages 487-510 Emergency Room Use of Opioid Antagonists in Drug Intoxication and Overdose....Pages 511-539 Kappa-Opioid Antagonists as Pruritogenic Agents....Pages 541-549 Clinical Effect of Opioid Antagonists on Clinical Pruritus....Pages 551-567 Effects of Opioid Antagonists on l -DOPA-Induced Dyskinesia in Parkinson's Disease....Pages 569-580 Endocrine Effects of Opioid Antagonists....Pages 581-604 Opioid Antagonists in Traumatic Shock: Animal and Human Studies....Pages 605-623 The Efficacy of Opioid Antagonists Against Heatstroke-Induced Ischemia and Injury in Rats....Pages 625-640 A Review of the Opioid System in Cancer Patients and Preliminary Results of Opioid Antagonists in the Treatment of Human Neoplasms....Pages 641-653 Nonclinical Pharmacology of VIVITROL ® : A Monthly Injectable Naltrexone for the Treatment of Alcohol Dependence....Pages 655-674 The Development of Sustained-Release Naltrexone and Clinical Use in Treating Opiate Dependence....Pages 675-688 The Development of ProNeura Technology for the Treatment of Addictions....Pages 689-708 Development of Opioid Transdermal Delivery Systems....Pages 709-728 Intranasal Naloxone for Treatment of Opioid Overdose....Pages 729-739 Back Matter....Pages 741-757

The evolution in our understanding of Opioid receptors and their subtypes is intimately linked to the development of new pharmacological treatments for diseases and disorders as diverse as addiction, self-injurious behavior, pain, cancer, inflammation, eating disorders, traumatic injury, pruritis and movement disorders. The contributions contained in Opioid Receptors and Antagonists: From Bench to Clinic represent efforts from leading international scientists and clinicians making use of the latest information emerging from the study of the opioid-receptor system. The authors use a variety of experimental and clinical approaches involving the fields of molecular biology, biochemistry, anatomy, pharmacology, behavioral neuroscience and psychiatry to illustrate rapidly developing experimental and therapeutic areas. Highlights include characterization of opioid receptors, chemistry and pharmacology of opiod antagonists for various receptor subtypes (Mu, Kappa, and Delta), discussion of therapeutic uses of opiod antagonists and exploration of innovative approaches to therapeutic drug delivery.

Opioid Receptors and Antagonists: From Bench to Clinic offers a comprehensive view of recent work on opiod antagonist applications and uses in various clinical treatments. Emphasis is placed on disorders of the reward system. This volume serves as reference while also illuminating prospects for future research.

Doody Review Services

Reviewer:Michael Easton, MD(Rush University Medical Center)
Description:This is an extensive review of the scientific research on opioid receptors and opioid receptor antagonists from theory to their applications and uses in various clinical conditions.
Purpose:This exceptional reference provides up-to-date reviews of the scientific literature and emerging data on the opioid-receptor system. It covers the basic science, including the molecular biology, biochemistry, anatomy, and pharmacology, and goes on to the clinical areas of behavioral neurosciences and psychiatric illnesses and how manipulation of this system affects various disorders.
Audience:This book is meant as a reference for both scientists and clinicians involved in the research or clinical application of opiate receptor antagonists.
Features:The history behind the development of the opioid antagonist naltrexone begins the book, which then goes on to review the characteristics of opioid receptors and describe the chemistry and pharmacology of opioid antagonists. It reviews the wide variety of clinical areas where these agents can be used: substance abuse (opiates, alcohol, nicotine and cannabis); behavioral disorders (appetite, eating disorders, mood disorders, pathological gambling, kleptomania, and self-injurious behavior); and other medical uses. The book finishes with a look at the development of innovative drug-delivery approaches being used with opioid antagonists.
Assessment:This is a comprehensive, detailed, and thorough reference on opiate receptors, opiate receptor antagonists, and the scientific data regarding their current use as well as potential clinical applications. The book also suggests future areas of research for the treatment of brain reward disorders as well as other medical indications where opioid receptor antagonists may be effective.

The evolution in our understanding of opioid receptors and their subtypes is in- mately linked to the development of new pharmacological treatments for diseases/ disorders as diverse as addiction, self-injurious behavior, pain, cancer, infl- mation, eating disorders, traumatic injury, pruritis, and movement disorders. These potential treatments involve both novel chemical entities and classic opioid antagonists with improved drug delivery systems. The contributions contained in Opioid Receptors and Antagonists: From Bench to Clinic represent the efforts from some of the leading international scientists and clinicians making use of the l- est information emerging from the study of the opioid receptor system. Given the number of researchers currently active in this and related fields of study, it would be inappropriate to suggest that the entire range of activities is fully reflected in this single volume. Instead, a variety of experimental and clinical approaches involving the fields of neuroscience, molecular biology, biochemistry, anatomy, pharmacology, psychology, and psychiatry have been chosen to illustrate rapidly developing experimental and therapeutic areas. Comprehensive and authoritative, Opioid Receptors and Antagonists: From Bench to Clinic offers neuroscientists, pharmacologists and interested clinicians a unique survey of the extensive and diverse research efforts currently employed with opioid antagonists to develop novel innovative drug therapies. Summarizes the present understanding of the chemistry, pharmacology and molecular biology of opioid receptors and their subtypes Highlights differences and similarities between the opioid pharmacology of animals and human Describes current and potential therapeutic areas for opioid antagonists, including substance abuse, alcohol and ingestive behaviors, behavioral disorders and other medical indications, supported by nonclinical and clinical evidence Focuses on the development of exciting and innovative drug delivery approaches that are being used with opioid antagonists for the above medical indications